Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics announces the initiation of the sixth cohort in its NCI-supported ReSPECT™ Phase 1 clinical trial, targeting recurrent glioblastoma with Rhenium NanoLiposomes (RNL™). This progression follows a successful fifth cohort, backed by the Data and Safety Monitoring Board’s clearance. Cohort six will increase both the drug volume to 8.8 mL and radiation dose to 22.3 millicuries. This trial is part of Plus Therapeutics’ strategy to enhance treatment efficacy for glioblastoma, with interim data presentation scheduled for the 2020 SNO Annual Meeting in November.
Plus Therapeutics (PSTV) received FDA Orphan Drug and Fast Track designations for its glioblastoma treatment Rhenium NanoLiposome (RNL). The company reported a third-quarter net loss of $1.7 million or $(0.39) per share, compared to a net income of $0.5 million or $(0.03) per share in Q3 2019. The cash balance decreased to approximately $7.6 million from $17.6 million at the end of 2019. The ReSPECT Phase 1 trial continues with enrollment in the sixth cohort approved. A conference call is scheduled for October 22, 2020, to discuss these results.
On October 15, 2020, Plus Therapeutics (Nasdaq: PSTV) announced its participation in the upcoming Cancer Innovation Summit hosted by Health Tech Austin, scheduled for October 22 from 12:00 to 3:00 p.m. EDT. Gregory Stein, M.D., Senior Vice President of Clinical Development, will present at the Cancer Drug Showcase, highlighting innovative cancer technologies. This summit aims to unite leaders to share insights on cancer innovation. Plus Therapeutics focuses on developing nanoliposome-encapsulated radionuclides targeting rare cancers, leveraging its unique nanotechnology platform for safer, more effective treatments.
Plus Therapeutics, Inc. (Nasdaq: PSTV) will release its third quarter 2020 financial results on October 22, 2020, after market close. A conference call will follow at 5:00 p.m. ET for management to discuss these results and provide corporate updates. The call will include a live webcast and can be accessed through their official IR page. Plus Therapeutics focuses on developing nanoliposome-encapsulated radionuclides targeted at rare cancers, aiming to enhance patient treatment through innovative drug delivery methods.
Plus Therapeutics, Inc. (Nasdaq: PSTV) has appointed five experts to its Clinical Advisory Board to enhance its efforts in developing nanoscale radiotherapeutics for rare brain cancers. The new members include leaders in neurological surgery and neuro-oncology from prestigious institutions. CEO Marc H. Hedrick emphasized the importance of their expertise in navigating clinical challenges, particularly for glioblastoma patients. Plus Therapeutics focuses on innovative drug delivery mechanisms, aiming to improve treatment efficacy and safety for patients.
Plus Therapeutics (Nasdaq: PSTV) announced its participation in the 22nd H. C. Wainwright Annual Global Investment Conference from September 14-16, 2020. The Company is scheduled to present on September 15 at 4:00 p.m. ET, with one-on-one meetings available during the event. The presentation will be live-streamed and accessible for later viewing. Plus Therapeutics focuses on developing innovative drug delivery systems targeting rare cancers, utilizing a unique nanotechnology platform to enhance treatment safety and efficacy. More details can be found on their corporate website.
Plus Therapeutics (Nasdaq: PSTV) announced its invitation to present at the 9th Annual Gateway Conference, scheduled for September 9-10, 2020. The management will present on September 10 at 3:30 p.m. ET. A live webcast of the presentation will be available for replay. Interested parties can schedule one-on-one meetings during the conference by contacting conference@gatewayir.com.
This conference connects compelling companies with top institutional investors, aimed at enhancing investor relations.
Plus Therapeutics, Inc. (PSTV) announced its participation in the LD 500 investor conference on September 4, 2020, at 10:20 AM ET. Dr. Marc Hedrick, the company's President and CEO, will present and engage in a Q&A session with investors. The conference occurs from September 1-4 and aims to provide a virtual platform for exposure to unique companies amid the COVID-19 pandemic. LD Micro's founder, Chris Lahiji, emphasizes accessibility for all participants. For more details, visit Plus Therapeutics' profile and register for the event.
Plus Therapeutics, Inc. (Nasdaq: PSTV) reported a Q2 2020 net loss of $1.8 million, or $0.45 per share, significantly reduced from a loss of $9.1 million, or $20.67 per share, in Q2 2019. The company ended the quarter with $9.3 million in cash. Key developments include ongoing clinical trials for Rhenium NanoLiposomes (RNL™) aimed at treating recurrent glioblastoma, with preliminary data expected soon. The firm plans to finalize its Phase 2 trial plan and seek Orphan Drug Designation while exploring partnerships for its oncology portfolio.
Plus Therapeutics (Nasdaq: PSTV) will release its Second Quarter Fiscal Year 2020 financial results after market close on August 10, 2020. A conference call at 5:00 PM ET will provide insights into the results and a business update. The company focuses on developing radiotherapeutics using its nanotechnology platform to target rare cancers. This technology enhances drug delivery and formulation for improved patient safety and convenience.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
